The non-pathogenic Escherichia coli strain Nissle 1917-features of a versatile probiotic

Microbial Ecology in Health and Disease

Volumn 21, Issue 3-4, 2009, Pages 122-158

  Sonnenborn, Ulrich ^a   Schulze, Jürgen ^a,b  

^a Ardeypharm GmbH   (Germany)

^b NONE   (Germany)

Author keywords

Biological activities; Clinical trials; EcN; Genetics; Medical history; Microbiology; Safety; Toxicological aspects

Indexed keywords

ACETIC ACID; AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZLOCILLIN; BACTERIUM LIPOPOLYSACCHARIDE; CEFACLOR; CEFAZOLIN; CEFOPERAZONE; CEFOTAXIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; CYTOTOXIN; DEFENSIN; DOXYCYCLINE; ESCHERICHIA COLI ENTEROTOXIN; GENTAMICIN; IMIPENEM; LACTULOSE; LATAMOXEF; MESALAZINE; MEZLOCILLIN; MUTAFLOR; NITROFURANTOIN; PLACEBO; PREDNISOLONE; PROBIOTIC AGENT; VEROTOXIN;

ABDOMINAL CRAMP; ACUTE DIARRHEA; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; BACTERIAL CHROMOSOME; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM ISOLATION; BIOLOGICAL ACTIVITY; BIOSAFETY; CANDIDIASIS; CLINICAL TRIAL; COLITIS; COLON MOTILITY; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ENTEROPATHY; ESCHERICHIA COLI; ESCHERICHIA COLI NISSLE 1917; FLATULENCE; FOOD INDUSTRY; GENE CLUSTER; GENE STRUCTURE; GENETIC STABILITY; GENOMIC ISLAND; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOTOXICITY; INTESTINE EPITHELIUM CELL; LISTERIOSIS; METABOLIC CAPACITY; MICROBIAL ACTIVITY; MICROBIAL METABOLISM; MOLECULAR GENETICS; NONHUMAN; PATHOGENICITY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TIGHT JUNCTION; ULCERATIVE COLITIS; VETERINARY MEDICINE;

ANIMALIA; BACTERIA (MICROORGANISMS); ENTEROBACTERIACEAE; ESCHERICHIA COLI; ESCHERICHIA COLI NISSLE 1917; LACTOCOCCUS; SACCHAROMYCES BOULARDII;

EID: 73649109180     PISSN: 0891060X     EISSN: 16512235     Source Type: Journal    
DOI: 10.3109/08910600903444267     Document Type: Review

References (268)

1. McCracken VJ, Lorenz RG. The gastrointestinal ecosystem: a precarious alliance among epithelium, immunity and microbiota. Cell Microbiol 2001;3:1-11.
2. Delcenserie V, Martel D, Lamoureux M, Amiot J, Boutin Y, Roy D. Immunomodulatory effects of probiotics in the intestinal tract. Curr Issues Mol Biol 2008;10:37-54.
3. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003;360:512-519
4. Ouwehand AC, Vaughan EE, editors. Gastrointestinal microbiology. New York: Taylor & Francis. 2006.
5. Rambaud JC, Buts JP, Corthier G, Flourie B, editors. Gut microflora-digestive physiology and pathology. Paris: John Libbey Eurotext. 2006.
6. Stecher B, Hardt WD. The role of microbiota in infectious disease. Trends Microbiol 2008;16:107-114
7. Yan F, Polk DB. Commensal bacteria in the gut: learning who our friends are. Curr Opin Gastroenterol 2004;20: 565-571
8. Chichlowski M, Hale LP. Bacterial-mucosal interactions in inflammatory bowel disease-an alliance gone bad. Am J Physiol Gastrointest Liver Physiol 2008;295: G1139-49.
9. Haenel H, Bendig J. Intestinal flora in health and disease. Prog Food Nutr Sci 1975;1:21-64.
10. Mai V, Draganov PV. Recent advances and remaining gaps in our knowledge of associations between gut microbiota and human health. World J Gastroenterol 2009;15:81-85
11. Savage DC. The ecological digestive system and its colonisation. Rev Sci Tech Off Int Epiz 1989;8:259-273
12. Schultz M, Scholmerich J, Rath HC. Rationale for probiotic and antibiotic treatment strategies in inflammatory bowel diseases. Dig Dis 2003;21:105-128
13. Schulze J, Sonnenborn U. The role of the gut flora in inflammatory bowel diseases. In: Shimoyama T, Axon A, Lee A, Podolsky DK, O'Morain C, editors. Helicobacter meets inflammatory bowel disease. Tokyo: Medical Tribune Inc. 2002. p. 393-417.
14. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge. N Engl J Med 2009; 360:439-443
15. Chadwick DJ, Goode J, editors. Antibiotic resistance: origins, evolution, selection and spread. Ciba Foundation Symposium 207. Chichester: John Wiley & Sons. 1997.
16. Davies J. Microbes have the last word. A drastic reevaluation of antimicrobial treatment is needed to overcome the threat of antibiotic-resistant bacteria. EMBO Rep 2007; 8:616-621
17. Hawkey PM. Action against antibiotic resistance: no time to lose. Lancet 1998;351:1298-1299
18. Witte W, Cuny C, Klare I, Nubel U, Strommenger B, Werner G. Emergence and spread of antibiotic-resistant gram-positive bacterial pathogens. Int J Med Microbiol 2008;298:365-377
19. Schulze J, Sonnenborn U, Olschlager T, Kruis W. Probiotika-Mikrookologie, Mikrobiologie, Qualitat, Sicherheit und gesundheitliche Effekte. Stuttgart: Hippokrates/Thieme. 2008.
20. Borchers AT, Selmi C, Meyers FJ, Keen CL, Gershwin ME. Probiotics and immunity. J Gastroenterol 2009;44:26-46.
21. Fric P. Probiotics in gastroenterology. Z Gastroenterol 2002;40:197-201.
22. Montrose DC, Floch MH. Probiotics used in human studies. J Clin Gastroenterol 2005;39:469-484
23. Sartor RB. Probiotic therapy of intestinal Inflammation and infections. Curr Opin Gastroenterol 2005;21:44-50.
24. Sullivan A, Nord CE. Probiotics and gastrointestinal diseases. J Intern Med 2005;257:78-92.
25. Tannock GW. Probiotics: time for a dose of realism. Curr Issues Intest Microbiol 2003;4:33-42.
26. FAO/WHO. 2001. Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. Cordoba, Argentina, 1-4 October 2001.
27. Vergin F. Anti-und Probiotika. Hippokrates 1954;25: 116-119
28. Lilly DM, Stillwell RH. Probiotics: growth-promoting factors produced by microorganisms. Science 1965;147: 747-748
29. Parker RB. Probiotics, the other half of the antibiotic story. Anim Nutr Health 1974;29:4-8.
30. Fuller R. Probiotics in man and animals. J Appl Bacteriol 1989;66:365-378
31. Guarner F, Schaafsma GJ. Probiotics. Int J Food Microbiol 1998;39:237-238
32. Elmer GW, Surawicz CM, McFarland LV. Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA 1996;275:870-876
33. McFarland LV, Bernasconi P. Saccharomyces boulardii: a review of an innovative biotherapeutic agent. Microb Ecol Health Dis 1993;6:157-171
34. Baumgart DC, Dignass AU. Current biological therapies for inflammatory bowel disease. Curr Pharm Des 2004;10: 4127-4147
35. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002;122:1592-1608
36. Sandborn WJ, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made? Gut 2004;53:1366-1373
37. Vermeire S, Rutgeerts P. Novel biological strategies in inflammatory bowel disease. Inflamm Bowel Dis 2004;10 (Suppl 1):S44-51. (Pubitemid 38332160)
38. Bansal T, Garg S. Probiotics: from functional foods to pharmaceutical products. Curr Pharm Biotechnol 2008;9: 267-287
39. Bengmark S. Bioecologic control of the gastrointestinal tract: the role of flora and supplemented probiotics and synbiotics. Gastroenterol Clin North Am 2005;34:413-436
40. Callaway TR, Edrington TS, Anderson RC, Harvey RB, Genovese KJ, Kennedy CN, et al. Probiotics, prebiotics and competitive exclusion for prophylaxis against bacterial disease. Anim Health Res Rev 2008;9:217-225
41. De Vrese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics. Adv Biochem Eng Biotechnol 2008;111:1-66.
42. Marteau P. Living drugs for gastrointestinal diseases: the case for probiotics. Dig Dis 2006;24:137-147
43. Gill H, Prasad J. Probiotics, immunomodulation, and health benefits. Adv Exp Med Biol 2008;606:423-454
44. Hart AL, Stagg AJ, Kamm MA. Use of probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol 2003;36:111-119
45. Heselmans M, Reid G, Akkermans LM, Savelkoul H, Timmerman H, Rombouts FM. Gut flora in health and disease: potential role of probiotics. Curr Issues Intest Microbiol 2005;6:1-7.
46. Reid G, Devillard E. Probiotics for mother and child. J Clin Gastroenterol 2004;38(Suppl 2):S94-101.
47. Schultz M. Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1012-1018
48. Nissle A. Die antagonistische Behandlung chronischer Darmstorungen mit Colibakterien. Med Klin 1918; 2:29-33.
49. Nissle A. Weiteres uber Grundlagen und Praxis der Mutafl orbehandlung. Dtsch Med Wochenschr 1925;44: 1809-1813
50. Hamilton-Miller JMT. A review of clinical trials of probiotics in the management of inflammatory bowel disease. Infect Dis Rev 2001;3:83-87
51. Krammer HJ, Kamper H, Von Bunau R, Ziesenis E, Stange C, Schlieger F, et al. Probiotische Arzneimitteltherapie mit E. coli Stamm Nissle 1917 (EcN): Ergebnisse einer prospektiven Datenerhebung mit 3807 Patienten. Z Gastroenterol 2006;44:651-656
52. Kruis W. Antibiotics and probiotics in inflammatory bowel disease. Aliment Pharmacol Ther 2004;20(s4):75-78
53. Blum-Oehler G, Oswald S, Eiteljorge K, Sonnenborn U, Schulze J, Kruis W, et al. Development of strain-specific PCR reactions for the detection of the probiotic Escherichia coli strain Nissle 1917 in fecal samples. Res Microbiol 2003;154:59-66.
54. Blum G, Marre R, Hacker J. Properties of Escherichia coli strains of serotype O6. Infection 1995;23:234-236
55. Grozdanov L, Zahringer U, Blum-Oehler G, Brade L, Henne A, Knirel YA, et al. A single nucleotide exchange in the wzy gene is responsible for the semirough O6 lipopolysaccharide phenotype and serum sensitivity of Escherichia coli strain Nissle 1917. J Bacteriol 2002;184:5912-5925
56. Grozdanov L, Raasch C, Schulze J, Sonnenborn U, Gottschalk G, Hacker J, et al. Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917. J Bacteriol 2004;186:5432-5441
57. Rietschel ET, Brade H, Holst O, Brade L, Muller-Loennies S, Mamat U, et al. Bacterial endotoxin: chemical constitution, biological recognition, host response, and immunological detoxifi cation. In: Rietschel ET, Wagner H, editors. Pathology of septic shock. Current Topics in Microbiology and Immunology, 216. Berlin: Springer-Verlag. 1996. p. 39-81. (Pubitemid 28012915)
58. Ott M, Bender L, Blum G, Schmittroth M, Achtman M, Tschape H, et al. Virulence patterns and long-range genetic mapping of extraintestinal Escherichia coli K1, K5, and K100 isolates: use of pulsed-field gel electrophoresis. Infect Immun 1991;59:2664-2672
59. Taylor PW. Bactericidal and bacteriolytic activity of serum against gram-negative bacteria. Microbiol Rev 1983; 47:46-83.
60. Hughes C, Phillips R, Roberts AP. Serum resistance among Escherichia coli strains causing urinary tract infection in relation to O type and the carriage of hemolysin, colicin, and antibiotic resistance determinants. Infect Immun 1982;35:270-275
61. Cario E. Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut 2005; 54:1182-1193
62. Wang Q, Suzuki A, Mariconda S, Porwollik S, Harshey RM. Sensing wetness: a new role for the bacterial flagellum. EMBO J 2005;24:2034-2042
63. Lasaro MA, Salinger N, Zhang J, Wang Y, Zhong Z, Goulian M, et al. F1C fimbriae play an important role in biofilm formation and intestinal colonization by the Escherichia coli commensal strain Nissle 1917. Appl Environ Microbiol 2009;75:246-251
64. Stentebjerg-Olesen B, Chakraborty T, Klemm P. Type 1 fimbriation and phase switching in a natural Escherichia colifimB null strain, Nissle 1917. J Bacteriol 1999;181: 7470-7478
65. Hammar M, Arnqvist A, Bian Z, Olsen A, Normark S. Expression of two csg operons is required for production of fi bronectin-and Congo red-binding curli polymers in Escherichia coli K-12. Mol Microbiol 1995;18:661-670
66. Olsen A, Jonsson A, Normark S. Fibronectin binding mediated by a novel class of surface organelles on Escherichia coli. Nature 1989;338:652-655
67. Ahmed N, Dobrindt U, Hacker J, Hasnain SE. Genomic fluidity and pathogenic bacteria: applications in diagnostics, epidemiology and intervention. Nat Rev Microbiol 2008;6: 387-394
68. Hacker J, Kaper JB. Pathogenicity islands and the evolution of microbes. Annu Rev Microbiol 2000;54:641-679
69. Hacker J, Carniel E. Ecological fitness, genomic islands and bacterial pathogenicity. A Darwinian view of the evolution of microbes. EMBO Rep 2001;2:376-381
70. Hacker J, Hentschel U, Dobrindt U. Prokaryotic chromosomes and disease. Science 2003;301:790-793
71. Grose C, Scherer J, Koch D, Otto M, Taudte N, Grass G. A new ferrous iron-uptake transporter, EfeU (YcdN), from Escherichia coli. Mol Microbiol 2006;62:120-131
72. Neilands JB. Mechanism and regulation of synthesis of aerobactin in Escherichia coli K12 (pColV-K30). Can J Microbiol 1992;30:728-733
73. Schubert S, Rakin A, Karch H, Carniel E, Heesemann J. Prevalence of the "high-pathogenicity island" of Yersinia species among Escherichia coli strains that are pathogenic to humans. Infect Immun 1998;66:480-485
74. Schubert S, Rakin A, Fischer D, Sorsa J, Heesemann J. Characterization of the integration site of Yersinia highpathogenicity island in Escherichia coli. FEMS Microbiol Lett 1999;179:409-414
75. Torres AG, Payne SM. Haem iron-transport system in enterohemorrhagic Escherichia coli O157:H7. Mol Microbiol 1997;23:825-833
76. Azpiroz MF, Rodriguez E, Lavina M. The structure, function, and origin of the microcin H47 ATP-binding cassette exporter indicate its relatedness to that of colicin V. Antimicrob Agents Chemother 2001;45:969-972
77. Gaggero C, Moreno F, Lavina M. Genetic analysis of microcin H47 antibiotic system. J Bacteriol 1993;175: 5420-5427
78. Rodriguez E, Gaggero C, Lavina M. The structural gene for microcin H47 encodes a peptide precursor with antibiotic activity. Antimicrob Agents Chemother 1999;43:2176-2182
79. Patzer SI, Baquero MR, Bravo D, Moreno F, Hantke K. The colicin G, H and X determinants encode microcins M and H47, which might utilize the catecholate siderophore receptors FepA, Cir, Fiu and IroN. Microbiology 2003; 149:2557-2570
80. Homburg S, Oswald E, Hacker J, Dobrindt U. Expression analysis of the colibactin gene cluster coding for a novel polyketide in Escherichia coli. FEMS Microbiol Lett 2007;275:255-262
81. Nougayrede JP, Homburg S, Taieb F, Boury M, Brzuszkiewicz E, Gottschalk G, et al. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science 2006;313:848-851
82. Zijlstra JB, Beukema J, Wolthers BG, Byrne BM, Groen A, Dankert J. Pretreatment methods prior to gas chromatographic analysis of volatile fatty acids from faecal samples. Clin Chim Acta 1977;78:243-250
83. Schmidt DS. Molekulare Analyse des probiotischen Stamms Escherichia coli Nissle 1917. Dissertation, Technische Universitat Dresden, 2009.
84. Dobrindt U. (Patho)-Genomics of Escherichia coli. Int J Med Microbiol 2005;295:357-371
85. Sun J, Gunzer F, Westendorf AM, Buer J, Scharfe M, Jarek M, et al. Genomic peculiarity of coding sequences and metabolic potential of probiotic Escherichia coli strain Nissle 1917 inferred from raw genome data. J Biotechnol 2005;117:147-161
86. Feldgarden M, Golden S, Wilson H, Riley MA. Can phage defence maintain colicin plasmids in Escherichia coli? Microbiology 1995;141:2977-2984
87. Reissbrodt R, Hammes WP, Dal Bello F, Prager R, Fruth A, Hantke K, et al. Inhibition of growth of Shiga toxinproducing Escherichia coli by nonpathogenic Escherichia coli. FEMS Microbiol Lett 2009;290:62-69
88. Sonnenborn U, Greinwald R. 1991. Beziehungen zwischen Wirtsorganismus und Darmflora unter besonderer Berucksichtigung von Physiologie und Funktion der normalen Escherichia-coli-Flora. Stuttgart: Schattauer Verlag.
89. Halbert SP. The antagonism of coliform bacteria against shigellae. J Immunol 1948;58:153-167
90. Mayr-Harting A, Hedges AJ, Berkeley RCW. Methods for studying bacterocins. Methods Microbiol 1972;7a: 315-422.
91. Denou E, Rezzonico E, Panoff JM, Arigoni F, Brussow H. A mesocosm of Lactobacillus johnsonii, Bifi dobacterium longum, and Escherichia coli in the mouse gut. DNA Cell Biol 2009;28:413-422
92. Lorenz A, Schulze J. Establishment of E. coli Nissle 1917 and its interaction with Candida albicans in gnotobiotic rats. Microecol Ther 1996;24:45-51.
93. Mandel L, Trebichavsky I, Splichal I, Schulze J. Stimulation of intestinal immune cells by E. coli in gnotobiotic piglets. In: Mestecky J, Russell MW, Jackson S, Michalek SM, Tlaskalova-Hogenova H, Sterzl J, editors. Advances in mucosal immunology. New York: Plenum Press. 1995. p. 463-464
94. Schulze J, Lorenz A, Mandel L. Colonisation of Escherichia coli in different gnotobiotic animal models. Microb Ecol Health Dis 1992;5:iv-v.
95. Leatham MP, Banerjee S, Autieri SM, Mercado-Lubo R, Conway T, Cohen PS. Precolonized human commensal Escherichia coli strains serve as a barrier to E. coli O157:H7 growth in the streptomycin-treated mouse intestine. Infect Immun 2009;77:2876-2886
96. Lodinova-Zadnikova R, Sonnenborn U. Effect of preventive administration of a nonpathogenic Escherichia coli strain on the colonization of the intestine with microbial pathogens in newborn infants. Biol Neonate 1997;71:224-232
97. Schroder H. Entwicklung der aeroben Darmflora bei Neugeborenen nach Kolonisierung mit dem E. coli-Stamm Nissle 1917. Der Kinderarzt 1992;23:1619-1625
98. Swidsinski A, Swidsinski S, Godzun A, Orthner M, Lochs H. Therapy with E. coli Nissle reduces concentrations of mucosa associated colonic flora in patients with ulcerative colitis. Gastroenterology 2000;118:A1138.
99. Altenhoefer A, Oswald S, Sonnenborn U, Enders C, Schulze J, Hacker J, et al. The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens. FEMS Immunol Med Microbiol 2004;40:223-229 (Pubitemid 38368186)
100. Oelschlaeger TA, Altenhoefer A, Hacker J. Inhibition of Salmonella typhimurium invasion into intestinal cells by the probiotic E. coli strain Nissle 1917. Gastroenterology 2001; 120(5 Suppl 1):A-326.
101. Boudeau J, Glasser AL, Julien S, Colombel JF, Darfeuille-Michaud A. Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn's disease. Aliment Pharmacol Ther 2003;18:45-56.
102. Duncker S. Auswirkung von oral verabreichtem Escherichia coli Nissle 1917 auf das Darm-assoziierte Immunsystem des Schweins. Dissertation, Tierarztl, Hochschule Hannover, 2005.
103. Duncker SC, Lorentz A, Schroeder B, Breves G, Bischoff SC. Effect of orally administered probiotic E. coli strain Nissle 1917 on intestinal mucosal immune cells of healthy young pigs. Vet Immunol Immunopathol 2006; 111:239-250
104. Hockertz S. Immunmodulierende Wirkung von abgetoteten apathogenen Escherichia coli Stamm Nissle 1917 auf das Makrophagensystem. Arzneim-Forsch/Drug Res 1991;41: 1108-1112
105. Cross ML, Ganner A, Teilab D, Fray LM. Patterns of cytokine induction by gram-positive and gram-negative probiotic bacteria. FEMS Immunol Med Microbiol 2004;42:173-180
106. Fink LN, Frokiaer H. Dendritic cells from Peyer's patches and mesenteric lymph nodes differ from spleen dendritic cells in their response to commensal gut bacteria. Scand J Immunol 2008;68:270-279
107. Helwig U, Lammers KM, Rizzello F, Brigidi P, Rohleder V, Caramelli E, et al. Lactobacilli, bifidobacteria and E. coli Nissle induce pro-and anti-inflammatory cytokines in peripheral blood mononuclear cells. World J Gastroenterol 2006;12:5978-5986
108. Kamada N, Maeda K, Inoue N, Hisamatsu T, Okamoto S, Hong KS, et al. Non-pathogenic Escherichia coli strain Nissle 1917 inhibits signal transduction in intestinal epithelial cells. Infect Immun 2008;76:214-220
109. Kramer S, Sellge G, Lorentz A, Krueger D, Schemann M, Feilhauer K, et al. Selective activation of human intestinal mast cells by Escherichia coli hemolysin. J Immunol 2008;181:1438-1445
110. Otte JM, Podolsky DK. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol 2004;286: G613-26.
111. Rasche C, Wolfram C, Wahls M, Worm M. Differential immunomodulating effects of inactivated probiotic bacteria on the allergic immune response. Acta Derm Venereol 2007; 87:305-311
112. Sturm A, Rilling K, Baumgart DC, Gargas K, Abou-Ghazale T, Raupach B, et al. Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infect Immun 2005;73:1452-1465
113. Ukena SN, Westendorf AM, Hansen W, Rohde M, Geffers R, Coldewey S, et al. The host response to the probiotic Escherichia coli strain Nissle 1917: specific up-regulation of the proinflammatory chemokine MCP-1. BMC Med Genet 2005;6:1-13.
114. Wehkamp J, Harder J, Wehkamp K, Wehkamp-von Meissner B, Schlee M, Enders C, et al. NF-B-and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun 2004;72:5750-5758
115. Zyrek AA, Cichon C, Helms S, Enders C, Sonnenborn U, Schmidt MA. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCZeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol 2007;9:804-816
116. Maeda K, Inoue N, Kamada N, Hong KS, Ogata H, Ishii H, et al. Non-pathogenic Escherichia coli inhibits signal transduction pathway in intestinal epithelia cells: a novel mechanism of action. Gastroenterology 2004;126(4 Suppl 2): A-577.
117. Otte JM, Mahjurian-Namari R, Brand S, Werner I, Schmidt WE, Schmitz F. Probiotics regulate the expression of COX-2 in intestinal epithelial cells. Nutr Cancer 2009;61:103-113
118. Grabig A, Paclik D, Dankof A, Baumgart DC, Erckenbrecht J, Raupach B, et al. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via Toll-like receptor 2-and Tolllike receptor 4-dependent pathways. Infect Immun 2006;74: 4075-4082
119. Guzy C, Paclik D, Schirbel A, Sonnenborn U, Wiedenmann B, Sturm A. The probiotic Escherichia coli strain Nissle 1917 induces gammadelta T cell apoptosis via caspase-and FasLdependent pathways. Int Immunol 2008;20:829-840
120. Trebichavsky I, Cukrowska B, Kozakova H, Schulze J, Rehakova Z, Sinkora J, et al. Association of germ-free piglets with two non-pathogenic E. coli strains: Nissle 1917 stimulates the immune system more than O86 strain. J Mol Med 1998;76:B-9.
121. Lodinova-Zadnikova R, Tlaskalova-Hogenova H, Sonnenborn U. Local and serum antibody response in fullterm and premature infants after artifi cial colonization of the intestine with E. coli strain Nissle 1917 (Mutafl or). Pediatr Allergy Immunol 1992;3:43-48
122. Cukrowska B, Lodinova-Zadnikova R, Enders C, Sonnenborn U, Schulze J, Tlaskalova-Hogenova H. Specific proliferative and antibody responses of premature infants to intestinal colonization with nonpathogenic probiotic E. coli strain Nissle 1917. Scand J Immunol 2002;55:204-209
123. Bohn E, Bechtold O, Zahir N, Frick JS, Reimann J, Jilge B, et al. Host gene expression in the colon of gnotobiotic interleukin-2-deficient mice colonized with commensal colitogenic or noncolitogenic bacterial strains: common patterns and bacteria strain specific signatures. Inflamm Bowel Dis 2006;12:853-862
124. Waidmann M, Bechtold O, Frick JS, Lehr HA, Schubert S, Dobrindt U, et al. Bacteroides vulgatus protects against Escherichia coli-induced colitis in gnotobiotic interleukin-2-deficient mice. Gastroenterology 2003;125:162-177
125. Arribas B, Rodriguez-Cabezas ME, Camuesco D, Comalada M, Ballon E, Utrilla P, et al. A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharideinduced sepsis in mice. Br J Pharmacol 2009;157:1024-1033
126. Hudcovic T, Stepankova R, Kozakova H, Hrncir T, Tlaskalova-Hogenova H. Effects of monocolonization with Escherichia coli strains O6K13 and Nissle 1917 on the development of experimentally induced acute and chronic intestinal Inflammation in germ-free immunocompetent and immunodeficient mice. Folia Microbiol 2007;52:618-626
127. Kamada N, Inoue N, Hisamatsu T, Okamoto S, Matsuoka K, Sato T, et al. Nonpathogenic Escherichia coli strain Nissle 1917 prevents murine acute and chronic colitis. Inflamm Bowel Dis 2005;11:455-463
128. Kokesova A, Frolova L, Kverka M, Sokol D, Rossmann P, Bartova J, et al. Oral administration of probiotic bacteria (E. coli Nissle, E. coli O83, Lactobacillus casei) Influences the severity of dextran sodium sulfate-induced colitis in BALB/c mice. Folia Microbiol 2006;51:478-484
129. Schultz M, Strauch UG, Linde HJ, Watzl S, Obermeier F, Gottl C, et al. Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal Inflammation in two different murine models of colitis. Clin Diagn Lab Immunol 2004;11:372-378
130. Ukena SN, Singh A, Dringenberg U, Engelhardt R, Seidler U, Hansen W, et al. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS One 2007;2:e1308.
131. Bickert T, Trujillo-Vargas CM, Duechs M, Wohlleben G, Polte T, Hansen G, et al. Probiotic Escherichia coli Nissle 1917 suppresses allergen-induced Th2 responses in the airways. Int Arch Allergy Immunol 2009;149:219-230
132. Hockertz S. Augmentation of host defence against bacterial and fungal infections of mice pretreated with the nonpathogenic Escherichia coli strain Nissle 1917. Arzneim-Forsch/Drug Res 1997;47(I):793-796
133. Von Bunau R, Jaekel L, Schubotz E, Schwarz S, Stroff T, Kruger M. Escherichia coli strain Nissle 1917: signifi cant reduction of neonatal calf diarrhea. J Dairy Sci 2005; 88:317-323
134. Clavel T, Haller D. Molecular interactions between bacteria, the epithelium, and the mucosal immune system in the intestinal tract: implications for chronic Inflammation. Curr Issues Intest Microbiol 2007;8:25-43.
135. Zoumpopoulou G, Tsakalidou E, Dewulf J, Pot B, Grangette C. Differential crosstalk between epithelial cells, dendritic cells and bacteria in a co-culture model. Int J Food Microbiol 2009;131:40-51.
136. Schultz M, Butt AG. Methodological aspects in probiotic research-a brief review with an emphasis on epithelial barrier function. Int J Probiotics Prebiotics 2007;2:85-96.
137. Cichon C, Enders C, Sonnenborn U, Schmidt MA. DNAmicroarray-based comparison of cellular responses in polarized T84 epithelial cells triggered by probiotics: E. coli Nissle 1917 (EcN) and Lactobacillus acidophilus PZ1041. Gastroenterology 2004;126(4 Suppl. 2):A-578-579
138. Wehkamp J, Harder J, Wehkamp-von Meissner B, Schwichtenberg L, Fellermann K, Herrlinger KR, et al. The probiotic E. coli Nissle 1917 (Mutafl or) induces defensins in intestinal epithelial cells: a novel mechanism of action. Gastroenterology 2002;122(4 Suppl):A75-6.
139. Schlee M, Wehkamp J, Altenhoefer A, Oelschlaeger TA, Stange EF, Fellermann K. Induction of human beta-defensin-2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect Immun 2007;75: 2399-2407
140. Hafez M, Hayes K, Goldrick M, Warhurst G, Grencis R, Roberts IS. The K5 capsule of Escherichia coli strain Nissle 1917 is important in mediating interactions with intestinal epithelial cells and chemokine induction. Infect Immun 2009;77:2995-3003.
141. Konturek PC, Brzozowski TM, Burnat G, Pajdo R, Hahn EG, Konturek SJ. Protective effects of probiotic Echerichia coli Nissle 1917 (EcN) bacterial strain against stress-induced acute gastric mucosal lesions. Gastroenterology 2007;132(4 Suppl S1):A-411.
142. Johne B, Fagerhol MK, Lyberg T, Prydz H, Brandtzaeg P, Naess-Andresen CF, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol 1997;50:113-123
143. Kido J, Kido R, Fagerhol MK, Nagata T. Calprotectin release from human neutrophils is induced by Porphyromonas gingivalis lipopolysacccharide via the CD14-Toll-like receptor-nuclear factor kappaB pathway. J Period Res 2003;38:557-563
144. Nisapakultorn K, Ross KF, Herzberg MC. Calprotectin expression inhibits bacterial binding to mucosal epithelial cells. Infect Immun 2001;69:3692-3696
145. Splichal I, Fagerhol MK, Trebichavsky I, Splichalova A, Schulze J. The effect of intestinal colonization of germ-free pigs with Escherichia coli on calprotectin levels in plasma, intestinal and bronchoalveolar lavages. Immunobiology 2005;209:681-687
146. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science 2001;292:1115-1118
147. Hord NG. Eukaryotic-microbiota crosstalk: potential mechanisms for health benefits of prebiotics and probiotics. Annu Rev Nutr 2008;28:215-231
148. Horswill AR, Nauseef WM. Host interception of bacterial communication signals. Cell Host Microbe 2008;4:507-509
149. Kohler H, McCormick BA, Walker WA. Bacterial-enterocyte crosstalk: cellular mechanisms in health and disease. J Pediatr Gastroenterol Nutr 2003;36:175-185
150. Spiller R, Campbell E. Post-infectious irritable bowel syndrome. Curr Opin Gastroenterol 2006;22:13-17
151. Spiller RC. Postinfective bowel dysfunction. Curr Opin Gastroenterol 1997;13:85-89
152. Liebregts T, Adam B, Bertel A, Jones S, Schulze J, Enders C, et al. Effect of E. coli Nissle 1917 on post-inflammatory visceral sensory function in a rat model. Neurogastroenterol Motil 2005;17:410-414
153. Bar F, von Koschitzky H, Roblick U, Bruch HP, Schulze L, Sonnenborn U, et al. Cell-free supernatants of Escherichia coli Nissle 1917 modulate human colonic motility: evidence from an in vitro organ bath study. Neurogastroenterol Motil 2009;21:559-566
154. Goel A, Mittal A, Evstatiev R, Nemeth M, Kruis W, Stolte M, et al. In vivo effects of mesalazine or E. coli Nissle 1917 on microsatellite instability in ulcerative colitis. Aliment Pharmacol Ther 2009;30:634-642
155. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53:1617-1623
156. Maron DM, Ames BN. Revised methods for the Salmonella mutagenicity test. Mutat Res 1983;113:173-215.
157. Speit G, Hartmann A. The comet assay: a sensitive genotoxicity test for the detection of DNA damage. Methods Mol Biol 2005;291:85-95.
158. Sonnenborn U, Janosch D, Dubbert S, Stroff T, Schulze L, Muller H. Antimutagenic activity of the probiotic E. coli strain Nissle 1917. J Crohn's Colitis 2009;3:136.
159. Schultz M, Watzl S, Olschlager T, Rath HC, Gottl C, Lehn N, et al. Green fl uorescent protein for detection of the probiotic microorganism Escherichia coli strain Nissle 1917 (EcN) in vivo. J Microbiol Methods 2005;61:389-398
160. Westendorf AM, Gunzer F, Deppenmeier S, Tapadar D, Hunger JK, Schmidt MA, et al. Intestinal immunity of Escherichia coli Nissle 1917: a safe carrier for therapeutic molecules. FEMS Immunol Med Microbiol 2005;43: 373-384
161. Nagy G, Dobrindt U, Grozdanov L, Hacker J, Emody L. Transcriptional regulation through RfaH contributes to intestinal colonization by Escherichia coli. FEMS Microbiol Lett 2005;244:173-180
162. Monteiro C, Saxena I, Wang X, Kader A, Bokranz W, Simm R, et al. Characterization of cellulose production in Escherichia coli Nissle 1917 and its biological consequences. Environ Microbiol 2009;11:1105-1116
163. Brombacher E, Dorel C, Zehnder AJB, Landini P. The curli biosynthesis regulator CsgD co-ordinates the expression of both positive and negative determinants for biofilm formation in Escherichia coli. Microbiology 2003;149:2847-2857
164. Kuhnert P, Hacker J, Muhldorfer I, Burnens AP, Nicolet J, Frey J. Detection system for Escherichia coli-specific virulence genes: absence of virulence determinants in B and C strains. Appl Environ Microbiol 1997;63:703-709
165. Ott M, Hoschutzky H, Jann K, Van Die I, Hacker J. Gene clusters for S fimbrial adhesin (sfa) and F1C fimbriae (foc) of Escherichia coli: comparative aspects of structure and function. J Bacteriol 1988;170:3983-3990
166. Zingler G, Ott M, Blum G, Falkenhagen U, Naumann G, Sokolowska-Kohler W, et al. Clonal analysis of Escherichia coli serotype O6 strains from urinary tract infections. Microb Pathog 1992;12:299-310.
167. Zingler G, Blum G, Falkenhagen U, Orskov I, Orskov F, Hacker J, et al. Clonal differentiation of uropathogenic Escherichia coli isolates of serotype O6:K5 by fimbrial antigen typing and DNA long-range mapping techniques. Med Microbiol Immunol 1993;182:13-24.
168. Valdebenito M, Crumbliss AL, Winkelmann G, Hantke K. Environmental factors Influence the production of enterobactin, salmochelin, aerobactin, and yersiniabactin in Escherichia coli strain Nissle 1917. Int J Med Microbiol 2006;296:513-520
169. Malchow H, Sonnenborn U, Greinwald R, Korner A. Colonization of adults by an apathogenic E. coli strain administered after gut decontamination. Gastroenterology 1995; 108:A-869.
170. Jores-Nguyen-Xuan TH, Boehm SK, Joeres L, Schulze J, Kruis W. Survival of
171. Prilassnig M, Wenisch C, Daxboeck F, Feierl G. Are probiotics detectable in human feces after oral uptake by healthy volunteers? Wien Klin Wochenschr 2007;119:1-7.
172. Bernardeau M, Guguen M, Vernoux JP. Benefi cial lactobacilli in food and feed: long-term use, biodiversity and proposals for specific and realistic safety assessments. FEMS Microbiol Rev 2006;30:487-513.
173. Besselink MGH, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008;371:651-659
174. Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr 2006;83:1256-1264
175. Ezendam J, Van Loveren H. Probiotics: immunomodulation and evaluation of safety and Efficacy. Nutr Rev 2006; 64:1-14.
176. Mattia A, Merker R. Regulation of probiotic substances as ingredients in foods: premarket approval or "generally recognized as safe" notification. Clin Infect Dis 2008;46 (Suppl 2): 115-118
177. Snydman DR. The safety of probiotics. Clin Infect Dis 2008;46(Suppl 2):104-111
178. Vankerckhoven V, Huys G, Vancanneyt M, Vael C, Klare I, Romond M-B, et al. Biosafety assessment of probiotics used for human consumption: recommendations from the EUPROSAFE project. Trends Food Sci Tech 2008;19:102-114
179. Wassenaar TM, Klein G. Safety aspects and implications of regulation of probiotic bacteria in food and food supplements. J Food Protect 2008;71:1734-1741
180. Blum G, Falbo V, Caprioli A, Hacker J. Gene clusters encoding the cytotoxic necrotizing factor type 1, Prsfimbriae and alpha-hemolysin form the pathogenicity island II of the uropathogenic Escherichia coli strain J96. FEMS Microbiol Lett 1995;126:189-195
181. Evans DJ Jr, Evans DG. Classifi cation of pathogenic Escherichia coli according to serotype and the production of virulence factors, with special reference to colonization-factor antigens. Rev Infect Dis 1983;5(Suppl 4):S692-701.
182. Levine MM. Escherichia coli that cause diarrhea: enterotoxigenic, enteropathogenic, enteroinvasive, enterohemorrhagic, and enteroadherent. J Infect Dis 1987;155:377-389
183. Nataro JP, Kaper JB. Diarrheagenic Escherichia coli. Clin Microbiol Rev 1998;11:142-201.
184. Orskov I, Orskov F. Escherichia coli in extra-intestinal infections. J Hyg 1985;95:551-575
185. Karch H, Meyer T. Evaluation of oligonucleotide probes for identifi cation of Shiga-like-toxin-producing Escherichia coli. J Clin Microbiol 1989;27:1180-1186
186. Mandel L, Travnicek J. The minipig as a model in gnotobiology. Die Nahrung 1987;31:613-617
187. Sereny B. Experimental keratoconjunctivitis Shigellosa. Acta Microbiol Hung 1957;4:367-376
188. Beutin L, Gleier K, Kontny I, Echeverria P, Scheutz F. Origin and characteristics of enteroinvasive strains of Escherichia coli (EIEC) isolated in Germany. Epidemiol Infect 1997;118:199-205.
189. Small PLC, Isberg RR, Falkow S. Comparison of the ability of enteroinvasive Escherichia coli, Salmonella typhimurium, Yersinia pseudotuberculosis, and Yersinia enterocolitica to enter and replicate within Hep-2-cells. Infect Immun 1987;55:1674-1679
190. Troger H, Richter J, Beutin L, Epple HJ, Fromm M, Zeitz M, et al. Wege der bakteriellen Translokation in Kolon-Epithelzellen unter dem Einfluss pro-Inflammatorischer Zytokine. Z Gastroenterol 2003;41:771.
191. Reeves P. Role of O-antigen variation in the immune response. Trends Microbiol 1995;3:381-386
192. Cassels FJ, Wolf MK. Colonization factors of diarrheagenic E. coli and their intestinal receptors. J Ind Microbiol 1995; 15:214-226
193. Zingler G, Schmidt G, Orskov I, Orskov F, Falkenhagen U, Naumann G. K-antigen identifi cation, hemolysin production, and hemagglutination types of Escherichia coli O6 strains isolated from patients with urinary tract infections. Zbl Bakt 1990;274:372-381
194. Gaastra W, Svennerholm AM. Colonization factors of human enterotoxigenic Escherichia coli (ETEC). Trends Microbiol 1996;4:444-452
195. Klemm P. Fimbrial adhesins of Escherichia coli. Rev Infect Dis 1985;7:321-340
196. Johnson JR. Virulence factors in Escherichia coli urinary tract infection. Clin Microbiol Rev 1991;4:80-128.
197. Marre R, Hacker J, Henkel W, Goebel W. Contribution of cloned virulence factors from uropathogenic Escherichia coli strains to nephropathogenicity in an experimental rat pyelonephritis model. Infect Immun 1986;54:761-767
198. NCCLS (National Committee for Clinical Laboratory Standards). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th edn. Approved standard M7-A4. 1997.
199. Frick JS, Zahir N, Kirschning C, Bohn E, Autenrieth IB. Commensal bacteria differentially modulate cytokine expression in dendritic cells. Int J Med Microbiol 2005; 295:131.
200. Bleich A, Sundberg JP, Smoczek A, Von Wasielewski R, De Buhr MF, Janus LM, et al. Sensitivity to Escherichia coli Nissle 1917 in mice is dependent on environment and genetic background. Int J Exp Pathol 2008;89:45-54.
201. Burmeister M, Ulanovsky L, editors. 1992. Pulsed-field gel electrophoresis; protocols, methods, and theories. Totowa, NJ: Humana Press.
202. Versalovic J, Koeuth T, Lupski JR. Distribution of repetitive DNA sequences in eubacteria and application to fi ngerprinting of bacterial genomes. Nucleic Acids Res 1991;19:6823-6831
203. Hardy KG, editor. 1987. Plasmids-a practical approach. Washington, DC: IRL Press.
204. Oswald S. Einfuhrung von Virulenz-assoziierten Antigenen in den Escherichia coli-Carrier-Stamm DSM 6601. Dissertation, Bayr. Julius-Maximilians-Universitat Wurzburg, 1997.
205. Datz M, Janetzki-Mittmann C, Franke S, Gunzer F, Schmidt H, Karch H. Analysis of the enterohemorrhagic Escherichia coli O157 DNA region containing lambdoid phage gene P and Shiga-like toxin structural genes. Appl Environ Microbiol 1996;62:791-797
206. Magistrelli C, Colombo E, Tognoni A, Grandi G. Transfection of E. coli with lambda DNA by electroporation. Microbiologica 1992;15:397-398
207. Smith HW, Green P, Parsell Z. Vero cell toxins in Escherichia coli and related bacteria: transfer by phage and conjugation and toxic action in laboratory animals, chickens, and pigs. J Gen Microbiol 1983;129:3121-3137
208. Krammer HJ, Schlieger F, Harder H, Franke A, Singer MV. Probiotika in der Therapie des Reizdarmsyndroms. Z Gastroenterol 2005;43:467-471
209. Kruis W, Chrubasik S, Stange C, Schulze J. Therapeutische Wirksamkeit des probiotischen E. coli-Stammes Nissle 1917 bei Reizdarm-Subgruppen. Z Gastroenterol 2004;42:785.
210. Plasmann D, Schulte-Witte H. Therapie des Reizdarmsyndroms mit Escherichia coli Stamm Nissle 1917 (EcN). Eine retrospektive Untersuchung. Med Klin 2007;102:888-892
211. Tromm A, Niewerth U, Khoury M, Baestlein E, Wilhelms G, Schulze J, et al. The probiotic E. coli strain Nissle 1917 for the treatment of collagenous colitis: first results of an openlabel trial. Z Gastroenterol 2004;42:365-369
212. Goerg KJ, Schlorer E. Probiotische Therapie einer pseudomembranosen Kolitis. Dtsch Med Wochenschr 1998; 123:1274-1278
213. Goerg KJ, Wybierala M, Rauen-Vossloh J, Hader C. A new approach in pseudomembranous colitis: probiotic Escherichia coli Nissle 1917 after intestinal lavage. Eur J Gastroenterol Hepatol 2008;20:155-156
214. Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J. Treatment of mild to moderate acute attacks of distal ulcerative colitis with rectally-administered E. coli Nissle 1917: dose-dependent Efficacy. Gastroenterology 2006;130(4 Suppl 2):A-119.
215. Malchow H. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997;25:653-658
216. Fric P, Zavoral M. The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol 2003;15:313-315
217. Kuzela L, Kascak M, Vavrecka A. Induction and maintenance of remission with nonpathogenic Escherichia coli in patients with pouchitis. Am J Gastroenterol 2001;96: 3218-3219
218. Henker J, Schuster F, Nissler K. Successful treatment of gut-caused halitosis with a suspension of living non-pathogenic Escherichia coli bacteria-a case report. Eur J Pediatr 2001;160:592-594
219. Lata J, Novotny I, Pribramska V, Jurankova J, Fric P, Kroupa R, et al. The effect of probiotics on gut flora, level of endotoxin and Child-Pugh score in cirrhotic patients: results of a double-blind randomized study. Eur J Gastroenterol Hepatol 2007;19:1111-1113
220. Wurzel RM. Prophylaxe der polymorphen Lichtdermatose. Aktuel Dermatol 1999;25:329-333
221. Hibi T, Inoue N, Ogata H, Naganuma M. Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease. J Gastroenterol 2003;38(Suppl 15): 36-42.
222. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental Influences. Gastroenterology 2004;126:1504-1517
223. Mathew CG, Lewis CM. Genetics of inflammatory bowel disease: progress and prospects. Hum Mol Genet 2004; 13:R161-8.
224. Danese S, Sans M, Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmunity Reviews 2004;3:394-400. (Pubitemid 38993362)
225. Mahida YR, Rolfe VE. Host-bacterial interactions in inflammatory bowel disease. Clin Sci 2004;107:331-341
226. Betsi GI, Papadavid E, Falagas ME. Probiotics for the treatment or prevention of atopic dermatitis: a review of the evidence from randomized controlled trials. Am J Clin Dermatol 2008;9:93-103.
227. Bohm SK, Kruis W. Probiotics. Do they help to control intestinal Inflammation? In: Domschke WW, Kagnoff MF, Kucharzik TF, Mayer LF, Targan SR, editors. Inflammatory bowel disease. Genetics, barrier function, immunologic mechanisms, and microbial pathways. Ann N Y Acad Sci 2006;1072:339-350
228. Duchmann R. The role of probiotics and antibiotics in regulating mucosal Inflammation. In: Neurath MF, Blumberg RS, editors. Immune mechanisms in inflammatory bowel disease. Advances in Experimental Medicine and Biology, 579. Berlin: Springer Science. 2006. p. 219-226
229. Ewaschuk JB, Dieleman LA. Probiotics and prebiotics in chronic inflammatory bowel diseases. World J Gastroenterol 2006;12:5941-5950
230. Fedorak RN, Dieleman LA. Probiotics in the treatment of human inflammatory bowel diseases: update 2008. J Clin Gastroenterol 2008;42(Suppl 2):S97-103.
231. Floch MH. Probiotics, irritable bowel syndrome, and inflammatory bowel disease. Curr Treat Options Gastroenterol 2003;6:283-288
232. Floch MH, Montrose DC. Use of probiotics in humans: an analysis of the literature. Gastroenterol Clin North Am 2005;34:547-570
233. Gionchetti P, Rizzello F, Lammers KM, Morselli C, Sollazzi L, Davies S, et al. Antibiotics and probiotics in treatment of inflammatory bowel disease. World J Gastroenterol 2006; 12:3306-3313 (Pubitemid 43933773)
234. Jones JL, Foxx-Orenstein AE. Probiotics in inflammatory bowel disease. Pract Gastroenterol 2006;30:44-50.
235. Kligler B, Hanaway P, Cohrssen A. Probiotics in children. Pediatr Clin North Am 2007;54:949-967
236. Kwon JH, Farrell RJ. Probiotics and inflammatory bowel disease. BioDrugs 2003;17:179-186
237. Marteau P, Seksik P, Jian R. Probiotics and intestinal health effects: a clinical perspective. Br J Nutr 2002;88(Suppl 1): S51-7.
238. Marteau P, Seksik P, Jian R. Probiotics and health: new facts and ideas. Curr Opin Biotechnol 2002;13:486-489
239. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004;126:1620-1633
240. Sartor RB. Microbial Influences in inflammatory bowel diseases. Gastroenterology 2008;134:577-594
241. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853-858
242. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon ATR. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635-639
243. Burke DA, Axon ATR. Adhesive Escherichia coli in inflammatory bowel disease and infective diarrhoea. BMJ 1988; 297:102-104
244. Hoffmann JC, Zeitz M, Bischoff SC, Brambs HJ, Bruch HP, Buhr HJ, et al. Diagnostik und Therapie der Colitis Ulcerosa: Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft fur Verdauungs-und Stoffwechselerkrankungen zusammen mit dem Kompetenznetz chronisch entzundliche Darmerkrankungen. Z Gastroenterol 2004;42:979-983
245. Stange EF, Riemann J, Von Herbay A, Lochs H, Fleig WE, Scholmerich J, et al. Diagnostik und Therapie der Colitis ulcerosa-Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft fur Verdauungs-und Stoffwechselkrankheiten. Leitlinien der DGVS. Z Gastroenterol 2001;39:19-72.
246. Travis SPL, Stange EF, Lemann M, Oresland T, Bemelman WA, Chowers Y, et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohn's Colitis 2008;2:24-62.
247. Vogelsang H, Tilg H, Petritsch W, Knoflach P. Colitis ulcerosa: medikamentose Rezidivprophylaxe. Osterreichische Arztezeitung 2003;1/2:40-41
248. Henker J, Muller S, Laass MW, Schreiner A, Schulze J. Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study. Z Gastroenterol 2008;46:874-875
249. Bruckschen E, Horosiewicz H. Chronische Obstipation, Vergleich von mikrobiologischer Therapie und Lactulose. Munch Med Wochenschr 1994;16:241-245
250. Mollenbrink M, Bruckschen E. Behandlung der chronischen Obstipation mit physiologischen Escherichia-coli-Bakterien. Med Klin 1994;89:587-593
251. Hernando-Harder AC, Von Bunau R, Nadarajah M, Singer MV, Harder H. Influence of E. coli Strain Nissle 1917 (EcN) on intestinal gas dynamics and abdominal sensation. Dig Dis Sci 2008;53:443-450
252. Henker J, Laass M, Blokhin BM, Bolbot YK, Maydannik VG, Elze M, et al. The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. Eur J Pediatr 2007;166:311-318
253. Henker J, Laass MW, Blokhin BM, Maydannik VG, Bolbot YK, Elze M, et al. Probiotic Escherichia coli Nissle 1917 versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers. Pediatr Infect Dis J 2008;27:494-499
254. Fuller R. History and development of probiotics. 1992. In: Fuller R, editor. Probiotics. London: Champman & Hall. p 1-8.
255. Bendali F, Sanaa M, Bichet H, Schelcher F. Risk factors associated with diarrhoea in newborn calves. Vet Res 1999;30:509-522 (Pubitemid 129582459)
256. Schroeder B, Duncker S, Barth S, Bauerfeind R, Gruber AD, Deppenmeier S, et al. Preventive effects of the probiotic Escherichia coli strain Nissle 1917 on acute secretory diarrhea in a pig model of intestinal infection. Dig Dis Sci 2006;51:724-731
257. Drisko JA, Giles CK, Bischoff BJ. Probiotics in health maintenance and disease prevention. Altern Med Rev 2003;8:143-155
258. Autieri SM, Lins JJ, Leatham MP, Laux DC, Conway T, Cohen PS. L-fucose stimulates utilization of D-ribose by Escherichia coli MG1655 (Delta)fucAO and E. coli Nissle 1917 (delta)fucAO mutants in the mouse intestine and in M9 minimal medium. Infect Immun 2007;75:5465-5475
259. Brader P, Stritzker J, Riedl CC, Zanzonico P, Cai S, Burnazi EM, et al. Escherichia coli Nissle 1917 facilitates tumor detection by positron emission tomography and optical imaging. Clin Cancer Res 2008;14:2295-2302
260. Coldewey SM, Hartmann M, Schmidt DS, Engelking U, Ukena S, Gunzer F. Impact of the rpoS genotype for acid resistance patterns of pathogenic and probiotic Escherichia coli. BMC Microbiol 2007;7:21.
261. Hejnova J, Pages D, Rusniok C, Glaser P, Sebo P, Buchrieser C. Specific regions of genome plasticity and genetic diversity of the commensal Escherichia coli A0 34/86. Int J Med Microbiol 2006;296:541-546
262. Mundy R, Girard F, FitzGerald AJ, Frankel G. Comparison of colonization dynamics and pathology of mice infected with enteropathogenic Escherichia coli, enterohaemorrhagic E. coli and Citrobacter rodentium. FEMS Microbiol Lett 2006;265:126-132
263. Stritzker J, Weibel S, Hill PJ, Oelschlaeger TA, Goebel W, Szalay AA. Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. Int J Med Microbiol 2007;297:151-162
264. Duan F, March JC. Interrupting Vibrio cholerae infection of human epithelial cells with engineered commensal bacterial signaling. Biotechnol Bioeng 2008;101:128-134
265. Duan F, Curtis KL, March JC. Secretion of insulinotropic proteins by commensal bacteria: rewiring the gut to treat diabetes. Appl Environ Microbiol 2008;74:7437-7438
266. Rao S, Hu S, McHugh L, Lueders K, Henry K, Zhao Q, et al. Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide. Proc Natl Acad Sci U S A 2005;102:1993-1998
267. Remer KA, Bartrow M, Roeger B, Moll H, Sonnenborn U, Oelschlaeger TA. Split immune response after oral vaccination of mice with recombinant Escherichia coli Nissle 1917 expressing fimbrial adhesin K88. Int J Med Microbiol 2009;299:467-478
268. Buddenborg C, Daudel D, Liebrecht S, Greune L, Humberg V, Schmidt MA. Development of a tripartite vector system for live oral immunization using a Gramnegative probiotic carrier. Int J Med Microbiol 2008;298: 105-114